A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST).
All of the activities carried out by the Institut Curie that enable it to fulfill its missions are carried out within the framework of 3 entities: a cutting-edge hospital complex in oncology, spread over three sites (Paris, Orsay and Saint-Cloud), internationally renowned research centers where more than 1,100 researchers work, distributed among 86 research teams, and the headquarters of the foundation.
Paris, France Clinical Trial Location
Institut Curie Hospital
26 Rue d’Ulm,
75005 Paris, France